Naltrexone Modification of Drinking Effects in a Subacute Treatment and Bar-Lab Paradigm: Influence of OPRM1 and Dopamine Transporter (SLC6A3) Genes
Alcoholism: Clinical and Experimental Research,  Clinical Article

Anton RF et al. – This study does not support a salient role for the opioid receptor (OPRM1) asp40 alone in predicting drinking or naltrexone effects. However, although exploratory and in need of replication, it introduces the possibility that epistasis between the OPRM1 gene and dopamine transporter gene might need to be taken into account when examining differential genetic response to alcohol or medication treatment, especially in early–stage alcoholics.

Methods
  • Two hundred and sixty-five nontreatment-seeking individuals with alcohol dependence were genotyped a priori for the OPRM1 asn40asp SNP and post hoc for DAT (SLC6A3) 9 and 10 VNTRs.
  • Asp40 carriers (n = 43) and matched asn40 homozygotes (n = 40) were randomized to naltrexone or placebo for 7 days before receiving a priming drink and limited-access alcohol consumption in a bar-lab setting.
  • Effects of genotypes on natural drinking as well as drinking, alcohol effects, and response to naltrexone in the bar-lab setting were examined by genotype.

Results
  • There were no significant main effects of naltrexone or OPRM1 genotype, or any medication by OPRM1 interaction, on drinking variables.
  • However, in individuals who had at least one DAT 9 VNTR, and who were also OPRM1 asn40 homozygotes, naltrexone reduced drinks/d consumed under natural conditions (p = 0.006), but not in the bar-lab.
  • OPRM1 asn40 homozygotes (p = 0.028) and DAT 9 VNTR carriers (p = 0.032) had more stimulation to alcohol after the priming drink.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study Journal of Affective Disorders, July 17, 2014    Clinical Article

2 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 28, 2014    Review Article    Clinical Article

3 Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder International Clinical Psychopharmacology, July 3, 2014    Clinical Article

4 A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression Journal of Affective Disorders, July 21, 2014    Evidence Based Medicine

5 Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: A meta-analysis of efficacy and acceptability Clinical Therapeutics, July 14, 2014    Evidence Based Medicine    Review Article

6 The effects of dehydroepiandrosterone (DHEA) in the treatment of depression and depressive symptoms in other psychiatric and medical illnesses: a systematic review Current Drug Targets, July 30, 2014    Review Article

7 Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials Australian and New Zealand Journal of Psychiatry, July 11, 2014    Clinical Article

8 Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials Psychosomatic Medicine, March 20, 2014    Evidence Based Medicine    Review Article    Clinical Article

9 Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants The Journal of Pediatrics, July 16, 2014    Clinical Article

10 Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: A nationwide register-based cohort study in Denmark CNS Drugs, June 18, 2014    Clinical Article

11 Do depression treatments reduce suicidal ideation?: The effects of CBT, IPT, pharmacotherapy, and placebo on suicidality Journal of Affective Disorders, July 24, 2014    Clinical Article

12 Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials Psychiatry Research, July 2, 2014    Evidence Based Medicine

13 Body mass index identified as an independent predictor of psychiatric readmission The Journal of Clinical Psychiatry, July 9, 2014    Clinical Article

14 Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study European Heart Journal, July 23, 2014

15 Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder American Journal of Health-System Pharmacy, July 8, 2014    Review Article

16 Efficacy and tolerability of antidepressants for sub-threshold depression and for mild major depressive disorder Journal of Affective Disorders, July 18, 2014    Evidence Based Medicine    Clinical Article

17 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis FOCUS, June 16, 2014    Evidence Based Medicine

18 Pretreatment brain states identify likely nonresponse to standard treatments for depression Biological Psychiatry, May 23, 2014    Clinical Article

19 Parental social responsiveness and risk of autism spectrum disorder in offspring JAMA Psychiatry, July 7, 2014    Clinical Article

20 Risk factors for the onset of panic and generalised anxiety disorders in the general adult population: A systematic review of cohort studies Journal of Affective Disorders, July 15, 2014    Evidence Based Medicine    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close